390 related articles for article (PubMed ID: 20132133)
1. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
2. Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat.
Abalo R; Cabezos PA; López-Miranda V; Vera G; González C; Castillo M; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2009 Sep; 21(9):1002-e80. PubMed ID: 19413685
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors.
Abalo R; Cabezos PA; Vera G; López-Miranda V; Herradón E; Martín-Fontelles MI
Neurogastroenterol Motil; 2011 May; 23(5):457-67, e177. PubMed ID: 21303434
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.
Izzo AA; Mascolo N; Capasso R; Germanò MP; De Pasquale R; Capasso F
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):221-3. PubMed ID: 10494894
[TBL] [Abstract][Full Text] [Related]
5. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat.
Coruzzi G; Adami M; Coppelli G; Frati P; Soldani G
Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):715-8. PubMed ID: 10619190
[TBL] [Abstract][Full Text] [Related]
7. The cannabinoid receptor agonist WIN 55,212-2 inhibits antigen-induced plasma extravasation in guinea pig airways.
Fukuda H; Abe T; Yoshihara S
Int Arch Allergy Immunol; 2010; 152(3):295-300. PubMed ID: 20150748
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
9. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
Liu Q; Bhat M; Bowen WD; Cheng J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats.
Germanò MP; D'Angelo V; Mondello MR; Pergolizzi S; Capasso F; Capasso R; Izzo AA; Mascolo N; De Pasquale R
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):241-4. PubMed ID: 11218077
[TBL] [Abstract][Full Text] [Related]
11. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
[TBL] [Abstract][Full Text] [Related]
12. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Burgos E; Pascual D; Martín MI; Goicoechea C
Eur J Pain; 2010 Jan; 14(1):40-8. PubMed ID: 19318283
[TBL] [Abstract][Full Text] [Related]
13. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.
Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M
Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676
[TBL] [Abstract][Full Text] [Related]
14. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoids inhibit noradrenergic and purinergic sympathetic cotransmission in the rat isolated mesenteric arterial bed.
Pakdeechote P; Dunn WR; Ralevic V
Br J Pharmacol; 2007 Nov; 152(5):725-33. PubMed ID: 17641668
[TBL] [Abstract][Full Text] [Related]
17. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
18. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
19. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
